Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 384


What are the most important unanswered research questions in trial retention? A James Lind Alliance Priority Setting Partnership: the PRioRiTy II (Prioritising Retention in Randomised Trials) study.

Brunsdon D, Biesty L, Brocklehurst P, Brueton V, Devane D, Elliott J, Galvin S, Gamble C, Gardner H, Healy P, Hood K, Jordan J, Lanz D, Maeso B, Roberts A, Skene I, Soulsby I, Stewart D, Torgerson D, Treweek S, Whiting C, Wren S, Worrall A, Gillies K.

Trials. 2019 Oct 15;20(1):593. doi: 10.1186/s13063-019-3687-7.


Preference of birth mode and postnatal health related quality of life after one previous caesarean section in three European countries.

Fobelets M, Beeckman K, Buyl R, Healy P, Grylka-Baeschlin S, Nicoletti J, Canepa M, Devane D, Gross MM, Morano S, Daly D, Begley C, Putman K.

Midwifery. 2019 Sep 19;79:102536. doi: 10.1016/j.midw.2019.102536. [Epub ahead of print]


Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, Wood SY, Spritzer C, Madden JF, Armstrong AJ.

Urol Oncol. 2019 Sep 12. pii: S1078-1439(19)30333-3. doi: 10.1016/j.urolonc.2019.08.015. [Epub ahead of print]


Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.

George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ.

Prostate. 2019 Nov;79(15):1752-1761. doi: 10.1002/pros.23899. Epub 2019 Sep 9.


Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Patel MP, Woodring S, Randazzo DM, Friedman HS, Desjardins A, Healy P, Herndon JE 2nd, McSherry F, Lipp ES, Miller E, Peters KB, Affronti ML.

Support Care Cancer. 2019 Aug 22. doi: 10.1007/s00520-019-05039-x. [Epub ahead of print]


Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.

Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.

Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]


Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.

Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ.

Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3.


A Core Outcome Set for the prevention and treatment of fetal GROwth restriction: deVeloping Endpoints: the COSGROVE study.

Healy P, Gordijn SJ, Ganzevoort W, Beune IM, Baschat A, Khalil A, Kenny L, Bloomfield FH, Daly M, Kirkham J, Devane D, Papageorghiou AT.

Am J Obstet Gynecol. 2019 Oct;221(4):339.e1-339.e10. doi: 10.1016/j.ajog.2019.05.039. Epub 2019 May 29.


Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.

J Immunother Cancer. 2019 May 29;7(1):142. doi: 10.1186/s40425-019-0614-0.


Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.

Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, Gerber D, Anand M, Foo WC, Halabi S, Gregory SG, George DJ.

PLoS One. 2019 May 28;14(5):e0216934. doi: 10.1371/journal.pone.0216934. eCollection 2019.


Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Desjardins A, Herndon JE 2nd, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Sampson JH, Randazzo D, Sommer N, Friedman AH, Friedman HS.

Health Sci Rep. 2019 Feb 13;2(4):e114. doi: 10.1002/hsr2.114. eCollection 2019 Apr.


MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y.

Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.


Influencing Decisions of Value in Health: A Response to Recent Commentaries.

Williams I, Brown H, Healy P.

Int J Health Policy Manag. 2019 Mar 1;8(3):187-188. doi: 10.15171/ijhpm.2018.116. No abstract available.


Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ.

Prostate Cancer Prostatic Dis. 2019 Apr 12. doi: 10.1038/s41391-019-0144-3. [Epub ahead of print]


Health economic analysis of a cluster-randomised trial (OptiBIRTH) designed to increase rates of vaginal birth after caesarean section.

Fobelets M, Beeckman K, Healy P, Grylka-Baeschlin S, Nicoletti J, Devane D, Gross MM, Morano S, Daly D, Begley C, Putman K.

BJOG. 2019 Jul;126(8):1043-1051. doi: 10.1111/1471-0528.15673. Epub 2019 Apr 7.


Labour characteristics of women achieving successful vaginal birth after caesarean section in three European countries.

Grylka-Baeschlin S, Clarke M, Begley C, Daly D, Healy P, Nicoletti J, Devane D, Morano S, Krause G, Karch A, Savage G, Gross MM.

Midwifery. 2019 Jul;74:36-43. doi: 10.1016/j.midw.2019.03.013. Epub 2019 Mar 19.


Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.


COSUTI: a protocol for the development of a core outcome set (COS) for interventions for the treatment of uncomplicated urinary tract infection (UTI) in adults.

Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, Healy P, Moore M, Little P, Devane D.

Trials. 2019 Feb 7;20(1):106. doi: 10.1186/s13063-019-3194-x.


Facile amidinations of 2-aminophenylboronic acid promoted by boronate ester formation.

Pappin BB, Garget TA, Healy PC, Simone MI, Kiefel MJ, Houston TA.

Org Biomol Chem. 2019 Jan 23;17(4):803-806. doi: 10.1039/c8ob02696c.


CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response.

Riccione KA, He LZ, Fecci PE, Norberg PK, Suryadevara CM, Swartz A, Healy P, Reap E, Keler T, Li QJ, Congdon KL, Sanchez-Perez L, Sampson JH.

Oncoimmunology. 2018 Sep 5;7(12):e1502904. doi: 10.1080/2162402X.2018.1502904. eCollection 2018.


Variation in outcome reporting in randomized controlled trials of interventions for prevention and treatment of fetal growth restriction.

Townsend R, Sileo F, Stocker L, Kumbay H, Healy P, Gordijn S, Ganzevoort W, Beune I, Baschat A, Kenny L, Bloomfield F, Daly M, Devane D, Papageorghiou A, Khalil A.

Ultrasound Obstet Gynecol. 2019 May;53(5):598-608. doi: 10.1002/uog.20189. Epub 2019 Apr 2. Review.


MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.

Lipp ES, Healy P, Austin A, Clark A, Dalton T, Perkinson K, Herndon JE, Friedman HS, Friedman AH, Bigner DD, McLendon RE.

J Neuropathol Exp Neurol. 2019 Jan 1;78(1):57-64. doi: 10.1093/jnen/nly110.


Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L.

Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13.


Rethinking the doctor-patient relationship: toward a hermeneutically-informed epistemology of medical practice.

Healy P.

Med Health Care Philos. 2019 Jun;22(2):287-295. doi: 10.1007/s11019-018-9875-5.


Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.

Affronti ML, Randazzo D, Lipp ES, Peters KB, Herndon SC, Woodring S, Healy P, Cone CK, Herndon JE 2nd, Schneider SM.

Semin Oncol Nurs. 2018 Dec;34(5):472-485. doi: 10.1016/j.soncn.2018.10.006. Epub 2018 Nov 6. Review.


Adjunctive perampanel for glioma-associated epilepsy.

Dunn-Pirio AM, Woodring S, Lipp E, Herndon JE 2nd, Healy P, Weant M, Randazzo D, Desjardins A, Friedman HS, Peters KB.

Epilepsy Behav Case Rep. 2018 Oct 9;10:114-117. doi: 10.1016/j.ebcr.2018.09.003. eCollection 2018.


Improving trial recruitment processes: how qualitative methodologies can be used to address the top 10 research priorities identified within the PRioRiTy study.

Hennessy M, Hunter A, Healy P, Galvin S, Houghton C.

Trials. 2018 Oct 25;19(1):584. doi: 10.1186/s13063-018-2964-1.


Virtual outpatient clinic as an alternative to an actual clinic visit after surgical discharge: a randomised controlled trial.

Healy P, McCrone L, Tully R, Flannery E, Flynn A, Cahir C, Arumugasamy M, Walsh T.

BMJ Qual Saf. 2019 Jan;28(1):24-31. doi: 10.1136/bmjqs-2018-008171. Epub 2018 Oct 5.


Development of an online resource for recruitment research in clinical trials to organise and map current literature.

Kearney A, Harman NL, Rosala-Hallas A, Beecher C, Blazeby JM, Bower P, Clarke M, Cragg W, Duane S, Gardner H, Healy P, Maguire L, Mills N, Rooshenas L, Rowlands C, Treweek S, Vellinga A, Williamson PR, Gamble C.

Clin Trials. 2018 Dec;15(6):533-542. doi: 10.1177/1740774518796156. Epub 2018 Aug 31. Review.


Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE).

Healy P, Gordijn S, Ganzevoort W, Beune I, Baschat A, Khalil A, Kenny L, Bloomfield F, Daly M, Papageorghiou A, Devane D.

Trials. 2018 Aug 22;19(1):451. doi: 10.1186/s13063-018-2819-9. Review.


Contextual Factors Influencing Cost and Quality Decisions in Health and Care: A Structured Evidence Review and Narrative Synthesis.

Williams I, Brown H, Healy P.

Int J Health Policy Manag. 2018 Aug 1;7(8):683-695. doi: 10.15171/ijhpm.2018.09. Review.


Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.

Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH.

J Clin Neurosci. 2018 Oct;56:163-168. doi: 10.1016/j.jocn.2018.06.005. Epub 2018 Jul 21.


Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.


Introducing the informed health choices project to Ireland.

Biesty L, Glynn D, Healy P, Chapman S, Devane D, Galvin S.

BMJ Evid Based Med. 2018 Jun;23(3):120. doi: 10.1136/bmjebm-2018-110936. Epub 2018 Mar 16. No abstract available.


A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.


Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership - the PRioRiTy (Prioritising Recruitment in Randomised Trials) study.

Healy P, Galvin S, Williamson PR, Treweek S, Whiting C, Maeso B, Bray C, Brocklehurst P, Moloney MC, Douiri A, Gamble C, Gardner HR, Mitchell D, Stewart D, Jordan J, O'Donnell M, Clarke M, Pavitt SH, Guegan EW, Blatch-Jones A, Smith V, Reay H, Devane D.

Trials. 2018 Mar 1;19(1):147. doi: 10.1186/s13063-018-2544-4.


Process Proteomics of Beer Reveals a Dynamic Proteome with Extensive Modifications.

Schulz BL, Phung TK, Bruschi M, Janusz A, Stewart J, Meehan J, Healy P, Nouwens AS, Fox GP, Vickers CE.

J Proteome Res. 2018 Apr 6;17(4):1647-1653. doi: 10.1021/acs.jproteome.7b00907. Epub 2018 Mar 1.


T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE.

Clin Cancer Res. 2018 Sep 1;24(17):4175-4186. doi: 10.1158/1078-0432.CCR-17-1846. Epub 2018 Feb 7.


Process evaluation for OptiBIRTH, a randomised controlled trial of a complex intervention designed to increase rates of vaginal birth after caesarean section.

Healy P, Smith V, Savage G, Clarke M, Devane D, Gross MM, Morano S, Daly D, Grylka-Baeschlin S, Nicoletti J, Sinclair M, Maguire R, Carroll M, Begley C.

Trials. 2018 Jan 5;19(1):9. doi: 10.1186/s13063-017-2401-x.


Synthesis of spirocyclic orthoesters by 'anomalous' rhodium(ii)-catalysed intramolecular C-H insertions.

Lombard FJ, Lepage RJ, Schwartz BD, Johnston RC, Healy PC, Krenske EH, Coster MJ.

Org Biomol Chem. 2018 Jan 3;16(2):256-261. doi: 10.1039/c7ob02123b.


Platinum sensitivity in metastatic prostate cancer: does histology matter?

Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):92-99. doi: 10.1038/s41391-017-0017-6. Epub 2017 Dec 11.


Mode of birth and postnatal health-related quality of life after one previous cesarean in three European countries.

Fobelets M, Beeckman K, Buyl R, Daly D, Sinclair M, Healy P, Grylka-Baeschlin S, Nicoletti J, Gross MM, Morano S, Putman K.

Birth. 2018 Jun;45(2):137-147. doi: 10.1111/birt.12324. Epub 2017 Dec 5.


Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.


Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.

Yi JS, Ready N, Healy P, Dumbauld C, Osborne R, Berry M, Shoemaker D, Clarke J, Crawford J, Tong B, Harpole D, D'Amico TA, McSherry F, Dunphy F, McCall SJ, Christensen JD, Wang X, Weinhold KJ.

Clin Cancer Res. 2017 Dec 15;23(24):7474-7482. doi: 10.1158/1078-0432.CCR-17-2005. Epub 2017 Sep 26.


5,6,7,3',4',5'-Hexamethoxyflavone from the Australian plant Eremophila debilis (Myoporaceae).

Butler MS, Healy PC, Forster PI, Guymer GP, Quinn RJ.

Fitoterapia. 2018 Apr;126:90-92. doi: 10.1016/j.fitote.2017.07.014. Epub 2017 Aug 1.


A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.

Randazzo DM, McSherry F, Herndon JE 2nd, Affronti ML, Lipp ES, Flahiff C, Miller E, Woodring S, Freeman M, Healy P, Minchew J, Boulton S, Desjardins A, Vlahovic G, Friedman HS, Keir S, Peters KB.

J Neurooncol. 2017 Sep;134(2):363-369. doi: 10.1007/s11060-017-2535-4. Epub 2017 Jul 1.


Vaginal birth after caesarean: Views of women from countries with low VBAC rates.

Nilsson C, Lalor J, Begley C, Carroll M, Gross MM, Grylka-Baeschlin S, Lundgren I, Matterne A, Morano S, Nicoletti J, Healy P.

Women Birth. 2017 Dec;30(6):481-490. doi: 10.1016/j.wombi.2017.04.009. Epub 2017 May 22.


Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ.

Eur J Cancer. 2017 Aug;81:228-236. doi: 10.1016/j.ejca.2017.02.030. Epub 2017 May 11.


Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH.

Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.


Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.

Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T.

Urol Oncol. 2017 Jun;35(6):418-424. doi: 10.1016/j.urolonc.2016.12.016. Epub 2017 Jan 23.


Supplemental Content

Support Center